Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Xoma reports unexpected setback in Neuprex development program

Sep. 28, 1999

Novel Na+/H+ exchange inhibitor presented at Japanese congress

Sep. 27, 1999

PST-2107, an Na+/K+-ATPase inhibitor with significant advantages over digoxin

Sep. 27, 1999

Dual NEP/ACE inhibitor attenuates left ventricular remodeling without affecting blood pressure

Sep. 27, 1999

SmithKline Beecham scientists identify urotensin-II receptor

Sep. 27, 1999

Patient enrollment complete in first of United Therapeutics' pulmonary hypertension trials

Sep. 24, 1999

rhIL-10 improves survival and attenuates myocardial damage in experimental viral myocarditis

Sep. 24, 1999

Complement inhibitor TP-10 enters infant trial for cardiopulmonary bypass

Sep. 24, 1999

Potentially beneficial cardiovascular effects of raloxifene uncovered

Sep. 23, 1999

FDA gives Vasogen go-ahead for TAA trial

Sep. 23, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...